Physician profile

Anthony E Webber

Orthopaedic Surgery · Jamaica Plain, MA

NPI 1225019466

$1,728.02

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$84.16

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Stryker Corporation $1,574.74 2019
Orthofix Medical, INC. $61.41 2021-2023 Physio-Stim
Pacira Pharmaceuticals Incorporated $23.77 2024 Zilretta, Iovera, Exparel
Pacira Therapeutics, INC. $19.29 2019
Depuy Synthes Sales INC. $17.70 2023 Orthovisc, Monovisc
Sanofi-Aventis U.S. LLC $16.99 2023
Smith+Nephew, INC. $14.12 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Anthony E Webber

$1,728.02

in general payments reported 2019-2025

Years
2019-2024
Top company
Stryker Corporation

https://glasscript.com/doctor/1195054/anthony-e-webber

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.